Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 5/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 5/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977717 | 1.00 | KLK7 (0.37) | KLK7BCHETDP1TLR2PPARG | |
| SCHEMBL30977742 | 0.99 | KLK7 (0.36) | KLK7BCHETDP1TLR2PPARG | |
| SCHEMBL30977701 | 0.96 | KLK7 (0.34) | KLK7BCHETDP1TLR2PPARG | |
| SCHEMBL30977769 | 0.95 | KLK7 (0.33) | KLK7BCHETDP1TLR2ACHE | |
| SCHEMBL30837979 | 0.91 | TLR2 (0.39) | TLR2PPARG | |
| SCHEMBL30977705 | 0.91 | TLR2 (0.39) | TLR2PPARG | |
| SCHEMBL30837985 | 0.91 | TLR2 (0.39) | TLR2PPARG | |
| SCHEMBL30977723 | 0.91 | TLR2 (0.39) | TLR2PPARG | |
| SCHEMBL30838052 | 0.91 | TLR2 (0.39) | TLR2PPARG | |
| SCHEMBL30837942 | 0.91 | TLR2 (0.39) | TLR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638417-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-12-05 | — | — | US | disclosed |
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | NANOVATION THERAPEUTICS INC. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-08-08 | — | — | US | disclosed |
| WO-2024130421-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | SLC43A1, NSUN3, NSUN2 | KLK7 3697/4885BCHE 3833/4885TDP1 3272/4885 |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | KLK7 3697/4885BCHE 3833/4885TDP1 3272/4885 |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | KLK7 3697/4885BCHE 3833/4885TDP1 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.